Keyphrases
Non-small Cell Lung Cancer (NSCLC)
67%
Malignant Pleural Mesothelioma
59%
Chemotherapy
55%
Pemetrexed
48%
Cisplatin
43%
ERCC1
41%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
40%
Non-small Cell Lung Cancer Patients
35%
Immunohistochemistry
34%
Overall Survival
32%
5-fluorouracil (5-FU)
31%
Vinorelbine
31%
Progression-free Survival
27%
Lung Cancer
26%
TUBB3
26%
Tumor
23%
EGFR mutation
23%
Thymidylate Synthase
23%
Carboplatin
21%
Cardiotoxicity
20%
Metastatic Non-small Cell Lung Cancer
20%
Paclitaxel
19%
Biomarker Expression
18%
Cell Association
17%
Matrix metalloproteinase-9 (MMP-9)
17%
Tissue Inhibitor of metalloproteinase-1 (TIMP-1)
17%
Colorectal Cancer Cells
17%
Patient Outcomes
17%
Caucasian Population
17%
Stroma Cells
17%
MiR-126
17%
Lugano
17%
Colorectal Cancer
17%
Diagnostic Biopsy
16%
Ki-67 Index
16%
Phase II Trial
15%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
89%
Chemotherapy
82%
Pleura Mesothelioma
60%
Overall Survival
46%
Pemetrexed
44%
Cisplatin
44%
Progression Free Survival
41%
Neoplasm
39%
Fluorouracil
38%
Biological Marker
36%
Adenocarcinoma
28%
Lung Cancer
26%
Diseases
24%
Colorectal Carcinoma
23%
Epidermal Growth Factor Receptor
22%
Mesothelioma
22%
Cardiotoxicity
20%
Gelatinase B
17%
Tubulin
17%
Tissue Inhibitor of Metalloproteinase 1
17%
Bevacizumab
17%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Lung Cancer
44%
Base Excision Repair
27%
Diseases
27%
Carboplatin
25%
Neoplasm
25%
Biopsy Technique
22%
Paclitaxel
22%
Progression Free Survival
20%
Diagnosis
20%
Epidermal Growth Factor Receptor
20%
Protein Expression
20%
Surgery
18%
Biological Marker
18%
Prevalence
17%
Smoking
17%
Cisplatin
16%
Bevacizumab
16%
